- Home
- » Tags
- » Pirfenidone
Top View
- Pirfenidone in Idiopathic Pulmonary Fibrosis
- Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
- (12) United States Patent (Lo) Patent No.: US 8,480,637 B2
- Possible Value of Antifibrotic Drugs in Patients with Progressive Fibrosing
- FLASH NOTE Vicore Pharma Holding AB (VICO-SE) OUTPERFORM Scleroderma the Second Indication for VP01 (C21) Target Price SEK42.00 Current Price SEK16.65
- Fibroblast-Enriched Endoplasmic Reticulum Protein TXNDC5 Promotes Pulmonary fibrosis by Augmenting Tgfβ Signaling Through TGFBR1 Stabilization
- Design and Rationale of Randomized, Double-Blind Trial of the Efficacy and Safety of Pirfenidone in Patients with Fibrotic Hypersensitivity Pneumonitis
- No Relevant Pharmacokinetic Drug-Drug Interaction Between Nintedanib and Pirfenidone
- Role and New Insights of Pirfenidone in Pulmonary Fibrotic Diseases
- Zāļu Patēriņa Statistika Statistics on Medicines Consumption
- Efficacy of Combination Therapy with Pirfenidone and Low-Dose
- Pirfenidone (Esbriet)
- Antifibrotic for Treatment of Idiopathic Pulmonary Fibrosis
- Repurposing Drugs for COVID-19 Based on Transcriptional Response of Host Cells to SARS-Cov-2
- Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
- Recent Advances of Nanotechnology-Facilitated Bacteria-Based Drug and Gene Delivery Systems for Cancer Treatment
- Reimbursement Criteria for Frequently Requested Drugs
- Extract from the Clinical Evaluation Report for Pirfenidone
- 022535Orig1s000
- First Drug for Idiopathic Pulmonary Fibrosis Approved in Japan
- Practical Approach to the Evaluation and Management of Rheumatoid Arthritis-Interstitial Lung Disease Based on Its Proven and Hypothetical Mechanisms
- Medications for Idiopathic Pulmonary Fibrosis: IPF Part 2
- Changes Highlighted Final Version Date of Issue
- USP Category USP Class Example Part D Eligible Drugs* Salt/Ester
- Effect of Pirfenidone on Wound Healing in Lung Transplant Patients Amber Mortensen1, Lauren Cherrier1 and Rajat Walia2*
- FDA Indications
- Proposed Additions to the NIOSH Hazardous Drug List 2018 Peer Review Comments
- Annual Report 2020 Vicore Pharma Holding AB (Publ)
- Who Is Taking Care of Me?
- JIA Guideline Appendix 4
- Antifibrotic Activities of Pirfenidone in Animal Models
- Pirfenidone (ESBRIET®) National Drug Monograph February 2015
- Dynamics in Diagnoses and Pharmacotherapy Before and After Diagnosing Idiopathic Pulmonary Fibrosis
- Supplementary Appendix
- Role and New Insights of Pirfenidone in Fibrotic Diseases
- Thalidomide Inhibits the Gene Promoter of Connective Tissue Growth Factor in Human Embryonic Lung Fibroblasts
- Drugs Formulary
- Chronic Inflammatory Disease (Updated December 2019)
- Repurposing Non-Cancer Drugs in Oncology – How Many Drugs Are out There?
- Clinical Trials on Drug Repositioning for COVID-19 Treatment
- Esbriet (Pirfenidone) Policy Number: C16582-A
- Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of Meeting on 10-13 February 2020
- A Retrospective Review Kelly Farrah, MLIS, AHIP; Danielle Rabb, MLIS
- 1111111111111111111Imnumu
- Pirfenidone in Patients with Unclassifiable Progressive Fibrosing Interstitial Lung Disease: Design of a Double-Blind, Randomised, Placebo- Controlled Phase II Trial
- Summary Review Summary Review of Regulatory Action
- An Update on Targeted Therapies in Systemic Sclerosis Based on a Systematic Review from the Last 3 Years Corrado Campochiaro1 and Yannick Allanore2*
- Drugs Limited to Specific Pharmacies | Kaiser Permanente Washington
- List Item Withdrawal Assessment Report for Esbriet
- Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative
- Dynamics in Diagnoses and Pharmacotherapy Before and After Diagnosing Idiopathic Pulmonary Fibrosis
- ESBRIET 267 Mg, Hard Capsules
- Pirfenidone (Esbriet®)
- Pirfenidone Pilot Study 0.Pdf
- Effect of Pirfenidone on Cough in Patients with Idiopathic Pulmonary Fibrosis